CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myelomaInger S. Nijhof(University Medical Center Utrecht), Niels W.C.J. van de Donk(Amsterdam UMC Location Vrije Universiteit Amsterdam)BloodJune 16, 201610.1182/blood-2016-03-703439Cited by 377SaveCiteExport RISWatch citationsRelated PapersCD38 antibodies in multiple myeloma: back to the future|Blood|2017|482Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab|Leukemia|2015|266